| |
| |
|
| Insider
Information: |
Mazar Andrew Paul |
| Relationship: |
|
| City: |
Wilmette |
| State: |
IL |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
22,125 |
|
|
Indirect Shares
|
4,277,940 |
|
|
| Direct
Value |
$14,872 |
|
|
|
Indirect Value
|
$2,875,631 |
|
|
| Total
Shares |
4,300,065 |
|
|
| Total
Value |
$2,890,504 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Monopar Therapeutics |
MNPR |
|
2022-03-31 |
22,125 |
2022-03-31 |
4,277,940 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
12 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2022-03-31 |
4 |
D |
$2.55 |
$1,201 |
D/D |
(471) |
22,125 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2022-03-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
22,596 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2022-01-01 |
4 |
D |
$3.21 |
$2,154 |
D/D |
(671) |
20,990 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,937 |
21,661 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-12-31 |
4 |
D |
$3.21 |
$1,785 |
D/D |
(556) |
19,724 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
20,280 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-09-30 |
4 |
D |
$4.87 |
$2,294 |
D/D |
(471) |
18,674 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-09-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,606 |
19,145 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-06-30 |
4 |
D |
$5.89 |
$5,548 |
D/D |
(942) |
17,539 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,212 |
18,481 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-01-01 |
4 |
D |
$6.12 |
$4,107 |
D/D |
(671) |
15,269 |
0 |
- |
|
| MNPR |
Monopar Therapeutics |
Chief Scientific Officer |
• • – |
2021-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,937 |
15,940 |
0 |
- |
|
12 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
